AstraZeneca and Merck asserted the approval of LYNPARZA tablets for patients with Ovarian Cancer
AstraZeneca and Merck asserted the sanctioning of LYNPARZA tablets for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded…
Read More...
Read More...
